| Back-ground |
Gene therapy development team at a leading academic health center was seeking substantial internal investment to advance a therapeutic asset for hemaglobinopathies (sickle cell etc). They also aspired to develop a best-in-class treatment center. However, they lacked a planning process to demonstrate commercial viability of the development plan.
|
|
|
| Challenges |
- No clear competitive assessment
- Diverging pre-clinical programs
- Incomplete clinical development plan
- No value proposition
|
|
|
| Solution |
ForeRunner helped the team complete a Target Product Profile development process. This process spanned 1.5 months and concluded in a 1-day workshop with the extended team and key stakeholders.
|
|
|
| Result |
The program was designated as core for the institution and received a multi-year funding commitment. The TPP outputs were cited as instrumental to characterizing the value of the investment and was used in justifying further investigation.
|
(267) 441-3254